Contineum Therapeutics Inc Class A Common Stock CTNM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
-
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
-
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
-
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
-
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
-
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Trading Information
- Previous Close Price
- $13.53
- Day Range
- $13.48–13.95
- 52-Week Range
- $4.85–16.89
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 37.39M
- Market Cap
- $519.67M
- Volume/Avg
- 171,501 / 302,213
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 51
- Website
- https://www.contineum-tx.com
Valuation
|
Metric
|
CTNM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.08 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CTNM
Financial Strength
|
Metric
|
CTNM
|
|---|---|
Quick Ratio | 37.00 |
Current Ratio | 38.00 |
Interest Coverage | — |
Quick Ratio
CTNM
Profitability
|
Metric
|
CTNM
|
|---|---|
Return on Assets (Normalized) | −21.24% |
Return on Equity (Normalized) | −22.51% |
Return on Invested Capital (Normalized) | −25.77% |
Return on Assets
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|zN<tzq! | LOCK|p^$t% | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|y>jvcq | LOCK|?!@Mr | $71B | |||
| argenx SE ADR
ARGX
| LOCK|M<pDwC | LOCK|!D> | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?gD!>&Q | LOCK|!s | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&Sp&@! | LOCK|@RXk | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|LSJ?jD%F | LOCK|<XWN | $26B | |||
| Moderna Inc
MRNA
| LOCK|Cj%Hm? | LOCK|&>< | $24B | |||
| Incyte Corp
INCY
| LOCK|m@HWrR | LOCK|^& | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^n>%KV@ | LOCK|f@# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&Sm>#@ | LOCK|mT | $16B |
United States